Freedom Finance and Binance Join Forces in Digital Assets 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
